ABSTRACT
INTRODUCTION: Vitiligo is a chronic skin condition with no cure. Clinical assessment and treatment evaluation relies heavily on clinometry tools and expert knowledge. The Vitiligo Extent Score has been proposed as one of the most reliable and easy-to-use clinometry tools for vitiligo. METHODS AND ANALYSIS: We proposed a scoping review to identify all the available evidence on the clinical research availability around the Vitiligo Extent Score. The following databases will be searched: MEDLINE (PubMed), Embase, Open Grey, Lens and Directory of Open Access Journals. In addition, the approach proposed in the Joanna Briggs Institute Reviewer's Manual will be followed. Finally, this review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. ETHICS AND DISSEMINATION: Ethics approval for this review is not required. We intend to publish the results in a specialised peer-reviewed journal and local, national and international conference presentations. It will also be incorporated as educational material in our institution's postgraduate programme in dermatology.
Subject(s)
Vitiligo , Humans , Academies and Institutes , Databases, Factual , Knowledge , MEDLINE , Research Design , Review Literature as Topic , Vitiligo/diagnosis , Vitiligo/therapyABSTRACT
Vitiligo is a chronic pigmentary condition and severely impacts patient quality of life (QoL). It is an underrecognized burden for patients, healthcare systems, and society in Latin America (LA). This paper examines the journey of a vitiligo patient in LA and assesses the disease landscape. Americas Health Foundation (AHF) assembled a panel of six Argentine, Brazilian, Colombian, and Mexican vitiligo experts. On 10-12 May 2022, they met in a virtual meeting. Each panelist wrote a short paper on barriers to vitiligo diagnosis and treatment in LA before the meeting. AHF staff moderated as the panel reviewed and modified each paper over three days. The panel approved the recommendations based on research, professional opinion, and personal experience. The panel agreed that lack of disease awareness and research, social ostracization, and limited therapeutic options hinder patients in their quest for diagnosis and treatment. In addition to the medical and psychological difficulties associated with vitiligo, problems connected to the Latin American healthcare system may negatively impact diagnosis, prognosis, and treatment. Access to timely diagnosis and treatment is crucial for improving outcomes. Governments, medical societies, academics, patient organizations, industry, and the public must unite to eliminate these challenges.
Subject(s)
Vitiligo , Humans , Latin America , Vitiligo/diagnosis , Vitiligo/therapy , Quality of Life , BrazilABSTRACT
Se presenta el caso de una paciente de 30 años quien consultó por un cuadro de 10 mesesde evolución, consistente en una placa única eritematosa, bien definida, con una costra en su superficie y de aproximadamente un centímetro de diámetro, poco pruriginosa, en ala nasalderecha. El estudio histológico, reveló acantolisis suprabasal y la inmunofluorescencia directa fue positiva sólo para IgG intercelular. Basados en los hallazgos clínicos e histopatológicos se hace undiagnóstico de pénfigo vulgar localizado. La lesión fue tratada con esteroide tópico de alta potencia,presentándose remisión completa a las dos semanas y luego de seis meses de seguimiento no se han registrado recurrencias.
A 30 years old female patient, with 10-month history ofa single erythematous, well defined plaque, with a cruston the surface, about one centimeter in diameter, slightly pruritic, in the right nasal wing. Histologic examination reported suprabasal acantholysis and direct immunofluorescence was positive for intercellular IgG deposits. Base don clinical and histopathological findings a diagnosis of pemphigus vulgaris localized was made. The patient was treated with high potency topical steroid, with complete remission of the lesion at two weeks of treatment and had no recurrences after six months of monitoring.
